ACE2 and COVID-19: A recombinant protein (ACE2-Ig), generated by fusing the extracellular domain of human ACE2 and Fc region of human IgG1, presents excellent pharmacological properties and high affinity to the receptor-binding domain of SARS-CoV and SARS-CoV-2 with promising outcome when used for diagnosis, prophylaxis, and treatment of SARS-CoV-2.[49] The renin-angiotensin aldosterone system inhibitors are potential candidates for COVID-19 treatment (Clinical Trial NCT04311177); however, the balance between the circulating ACE2 and membrane-bound ACE2 receptor levels is crucial.[50]